• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Syra Health Corp.

    2/20/24 3:01:17 PM ET
    $SYRA
    Diversified Commercial Services
    Consumer Discretionary
    Get the next $SYRA alert in real time by email
    SC 13G 1 formsc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. ________)*

     

    Syra Health Corp

     

    (Name of Issuer)

     

     

    Class A Common Stock

     

    (Title of Class of Securities)

     

    87168W203

     

    (CUSIP Number)

     

     

     

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    February 8, 2024

     

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
    CUSIP No. 87168W20313GPage 2 of 5 Pages

     

    1.

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Mike Edward McAleer

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a) ☐

    (b) ☐

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Canada

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    32467

    6.

    SHARED VOTING POWER

     

    32467

    7.

    SOLE DISPOSITIVE POWER

     

    00,000

    8.

    SHARED DISPOSITIVE POWER

     

    00,000

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    00,000

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions) ☐

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    000%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

     

     

     
    CUSIP No. 87168W20313GPage 3 of 5 Pages

     

    Item 1.

     

      (a)

    Name of Issuer

     

    Syra Health Corp

         
      (b)

    Address of Issuer’s Principal Executive Offices

     

    1119 Keystone Way Carmel, IN 46032

     

    Item 2.

     

      (a)

    Name of Person Filing

     

    Mike Edward McAleer

         
      (b)

    Address of the Principal Office or, if none, residence

     

    2608 Point Grey Road Vancouver BC Canada V6K 1A5

         
      (c)

    Citizenship

     

    Canada

         
      (d)

    Title of Class of Securities

     

    Class A Common

         
      (e)

    CUSIP Number

     

    87168W203

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

     
    CUSIP No. 87168W20313GPage 4 of 5 Pages

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)  

    Amount beneficially owned: 32,467

           
      (b)  

    Percent of class: 0.002

           
      (c)   Number of shares as to which the person has: 00,000
           
          (i)

    Sole power to vote or to direct the vote.

             
          (ii)

    Shared power to vote or to direct the vote.

             
          (iii)

    Sole power to dispose or to direct the disposition of.

             
          (iv)

    Shared power to dispose or to direct the disposition of.

     

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Instruction. Dissolution of a group requires a response to this item.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Item 9. Notice of Dissolution of Group.

     

    Item 10. Certification.

     

      (a) The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):
         
        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
         
      (b) The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):
         
        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 87168W20313GPage 5 of 5 Pages

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    February 20, 2024

      Date
       
      /s/ Mike Edward McAleer
      Signature
       
      Mike Edward McAleer/Principal
      Name/Title

     

     

     

    Get the next $SYRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SYRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SYRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Syra Health Selected for $5.8 Million Indiana Child Mental Health Program

      CARMEL, Ind., May 27, 2025 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA) ("Syra Health" or the "Company"), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today that the Indiana Department of Administration in collaboration with the Family and Social Services Administration/Division of Mental Health and Addiction has recommended Syra Health for contract negotiations to implement Indiana's Child Mental Health Wraparound Access Site. The contract is valued at $5.8 million over three years, with an optional one-year extension. Syra has committed to subcontracting 23.5% of the total contract value to other Indian

      5/27/25 8:55:00 AM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary
    • Syra Health Board Begins CEO Search to Drive Growth

      CARMEL, Ind., May 20, 2025 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA) ("Syra Health" or the "Company"), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today that its Board of Directors will begin a national search for a new Chief Executive Officer to succeed current CEO Dr. Deepika Vuppalanchi. Dr. Vuppalanchi will serve as interim CEO until a successor is appointed. This leadership transition is part of a strategic succession plan designed to position Syra Health for its next phase of grow

      5/20/25 9:00:00 AM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary
    • Syra Health Announces First Quarter Revenue of $1.9 Million, Up 6% YoY

      Revenue increase led by Population Health's 261% YoY Expansion Gross Margin Improves Substantially to 31.7%, up 14.6 Percentage Points YoY Continued Efficiency Gains Cut Q1 2025 Net Losses by Over Two Thirds Compared to Q1 2024 A conference call will be held today, Thursday, May 8, at 9:00 am ET CARMEL, Ind., May 8, 2025 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA) ("Syra Health" or the "Company"), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today its financial results for the first quarter ended March 31, 2025.

      5/8/25 7:55:00 AM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary

    $SYRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO and COO Prasad Priya bought $13,257 worth of shares (14,448 units at $0.92) and sold $10,144 worth of shares (4,153 units at $2.44) (SEC Form 4)

      4 - Syra Health Corp (0001922335) (Issuer)

      9/13/24 9:10:53 AM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary

    $SYRA
    SEC Filings

    See more
    • Syra Health Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Syra Health Corp (0001922335) (Filer)

      5/20/25 4:30:24 PM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary
    • Syra Health Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Syra Health Corp (0001922335) (Filer)

      5/8/25 4:45:37 PM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary
    • SEC Form 10-Q filed by Syra Health Corp.

      10-Q - Syra Health Corp (0001922335) (Filer)

      5/8/25 4:30:29 PM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary

    $SYRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Rogers Sherron

      4 - Syra Health Corp (0001922335) (Issuer)

      1/8/25 8:39:45 PM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary
    • SEC Form 4 filed by Director Dahlem Andrew

      4 - Syra Health Corp (0001922335) (Issuer)

      1/8/25 8:39:48 PM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary
    • SEC Form 4 filed by Director Paranjape Ketan

      4 - Syra Health Corp (0001922335) (Issuer)

      1/8/25 8:39:43 PM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary

    $SYRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Syra Health Board Begins CEO Search to Drive Growth

      CARMEL, Ind., May 20, 2025 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA) ("Syra Health" or the "Company"), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today that its Board of Directors will begin a national search for a new Chief Executive Officer to succeed current CEO Dr. Deepika Vuppalanchi. Dr. Vuppalanchi will serve as interim CEO until a successor is appointed. This leadership transition is part of a strategic succession plan designed to position Syra Health for its next phase of grow

      5/20/25 9:00:00 AM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary

    $SYRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Syra Health Corp.

      SC 13G - Syra Health Corp (0001922335) (Subject)

      2/20/24 3:01:17 PM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary

    $SYRA
    Financials

    Live finance-specific insights

    See more
    • Syra Health Announces First Quarter Revenue of $1.9 Million, Up 6% YoY

      Revenue increase led by Population Health's 261% YoY Expansion Gross Margin Improves Substantially to 31.7%, up 14.6 Percentage Points YoY Continued Efficiency Gains Cut Q1 2025 Net Losses by Over Two Thirds Compared to Q1 2024 A conference call will be held today, Thursday, May 8, at 9:00 am ET CARMEL, Ind., May 8, 2025 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA) ("Syra Health" or the "Company"), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today its financial results for the first quarter ended March 31, 2025.

      5/8/25 7:55:00 AM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary
    • Syra Health To Discuss First Quarter 2025 Financial Results

      Conference call will be held on Thursday, May 8, at 9:00 a.m. ET CARMEL, Ind., May 1, 2025 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA), ("Syra Health" or the "Company"), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today that it will report financial results for the three months ended March 31, 2025, on Thursday, May 8, 2025, before market open. The Company will host a conference call that same day, May 8, 2025, at 9:00 a.m. ET, to discuss the results. Interested parties can access the con

      5/1/25 8:55:00 AM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary
    • Syra Health Announces Full-Year Revenue of $8.0 Million, Up 45% YoY

      2024 Population Health Revenue Acceleration to 132% YoY Q4 2024 Net Losses Cut Nearly in Half Compared to Q4 2023, Highlighting Major Efficiency Gains Continued Momentum with New Customer Wins and Contract Extensions Driving Sustainable Growth A conference call will be held today, Tuesday, March 11 at 9:00 am ET CARMEL, Ind., March 11, 2025 /PRNewswire/ -- Syra Health Corp. (NASDAQ:SYRA) ("Syra Health" or the "Company"), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today its financial results for fourth quarter and full year ended December 31, 2024.

      3/11/25 7:43:00 AM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary